Starling Oncology (STLNW) Other Operating Expenses (2021 - 2026)

Starling Oncology (STLNW) has reported Other Operating Expenses for 6 consecutive years, with $134.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses rose 30.81% year-over-year to $134.8 million; the trailing twelve-month figure through Jun 2026 stood at $497.9 million (up 36.9% YoY), and the FY2025 full-year result was $429.3 million, up 25.33% from the prior year.
• Other Operating Expenses grew to $134.8 million in Q2 2026 per STLNW's latest filing, from $124.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $134.8 million in Q2 2026 and bottomed at $43.5 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $85.0 million across 5 years, with a median of $84.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses soared 83.14% in 2023, then climbed 4.75% in 2024.
• Over 5 years, Other Operating Expenses stood at $66.5 million in 2022, then increased by 8.59% to $72.2 million in 2023, then climbed by 19.71% to $86.4 million in 2024, then jumped by 38.78% to $119.9 million in 2025, then increased by 12.45% to $134.8 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $134.8 million, $124.8 million, and $119.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.